Biogen, Eisai's Alzheimer's Drug Deemed Too Costly for UK National Health Service
Biogen, Eisai's Alzheimer's Drug Deemed Too Costly for UK National Health Service
渤健公司和艾兹公司的阿尔茨海默病药物被认为对英国国家医疗服务体系成本太高
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册